Patrick Cunningham Sells 12,759 Shares of Aveanna Healthcare (NASDAQ:AVAH) Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) insider Patrick Cunningham sold 12,759 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $7.65, for a total value of $97,606.35. Following the completion of the transaction, the insider owned 374,156 shares in the company, valued at approximately $2,862,293.40. This trade represents a 3.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Aveanna Healthcare Stock Performance

Aveanna Healthcare stock traded up $0.02 during mid-day trading on Thursday, reaching $7.42. 3,877,110 shares of the stock traded hands, compared to its average volume of 938,081. Aveanna Healthcare Holdings Inc. has a 12-month low of $3.67 and a 12-month high of $10.32. The business’s 50-day moving average is $8.48 and its 200-day moving average is $8.44. The company has a debt-to-equity ratio of 140.39, a current ratio of 1.23 and a quick ratio of 1.23. The stock has a market capitalization of $1.55 billion, a PE ratio of 20.61 and a beta of 2.06.

Institutional Investors Weigh In On Aveanna Healthcare

Institutional investors and hedge funds have recently bought and sold shares of the business. AustralianSuper Pty Ltd bought a new position in shares of Aveanna Healthcare during the 3rd quarter valued at approximately $15,743,000. Vanguard Group Inc. raised its stake in Aveanna Healthcare by 38.0% during the fourth quarter. Vanguard Group Inc. now owns 5,577,010 shares of the company’s stock valued at $45,564,000 after purchasing an additional 1,535,351 shares in the last quarter. Millennium Management LLC raised its stake in Aveanna Healthcare by 1,007.1% during the fourth quarter. Millennium Management LLC now owns 1,114,717 shares of the company’s stock valued at $9,107,000 after purchasing an additional 1,014,030 shares in the last quarter. Nuveen LLC lifted its position in Aveanna Healthcare by 135.9% during the fourth quarter. Nuveen LLC now owns 1,571,308 shares of the company’s stock valued at $12,838,000 after purchasing an additional 905,316 shares during the last quarter. Finally, Hillsdale Investment Management Inc. purchased a new position in shares of Aveanna Healthcare in the 3rd quarter worth $7,922,000. 87.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on AVAH shares. Zacks Research downgraded shares of Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 3rd. Raymond James Financial reiterated an “outperform” rating and issued a $13.00 price target on shares of Aveanna Healthcare in a research report on Friday, December 5th. UBS Group lifted their price target on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “neutral” rating in a research note on Thursday, January 15th. Weiss Ratings reissued a “hold (c+)” rating on shares of Aveanna Healthcare in a research report on Monday, December 29th. Finally, Truist Financial raised their target price on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “hold” rating in a report on Friday, November 7th. Five equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $11.06.

Aveanna Healthcare News Summary

Here are the key news stories impacting Aveanna Healthcare this week:

• Neutral Sentiment: Short-interest data released for Feb. 19 shows an apparent data anomaly (0 shares reported / NaN change), so there’s no clear short‑interest signal to explain price moves today. (Report notes the short‑interest ratio is effectively 0 days based on reported volume.)
• Neutral Sentiment: Market commentary explains recent intraday weakness in AVAH; see a recent write‑up for context on why the stock moved. Why AVAH is Down
• Negative Sentiment: Significant insider selling: over Feb. 17–19 multiple insiders (CEO Jeff Shaner, several executives including CFO Matthew Buckhalter and CAO Deborah Stewart, plus others such as Edwin C. Reisz and Patrick A. Cunningham) sold large blocks. Combined, these filings show roughly 740,000 shares sold across the group — about $5.4–$5.5M in proceeds — at average prices in the ~$7.20–$7.65 range. Collective, high‑profile sales of this size often weigh on near‑term investor sentiment because they increase supply and may be interpreted as insiders taking money off the table. CEO Filings Other Exec Filings

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.